Enliven Therapeutics appoints Dr. Lori Kunkel to Board of Directors

Enliven Therapeutics, Inc.

Dr. Kunkel appointed as Class III director, term expiring at 2026 annual meeting.
Annual cash retainer of $35,000; stock option grant with fair value ~$500,000 vesting monthly over 3 years.
No arrangements or transactions requiring disclosure under Item 404(a) of Reg S-K.
Dr. Kunkel brings 25+ years oncology drug development experience; previously scientific advisor to Enliven.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Lori Kunkel

Class III Director

ELVN · Enliven Therapeutics, Inc.

Effective: 2024-04-08
Filed: April 9, 2024, 7:59 PM ET

On April 8, 2024, the Board of Directors (the “Board”) of Enliven Therapeutics, Inc. (the “Company”) appointed Lori Kunkel, MD to serve as a Class III director, with a term expiring at the Company’s 2026 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Lori Kunkel was appointed as Class III Director at Enliven Therapeutics, Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

On April 8, 2024, the Board of Directors (the “Board”) of Enliven Therapeutics, Inc. (the “Company”) appointed Lori Kunkel, MD to serve as a Class III director, with a term expiring at the Company’s 2026 annual meeting of stockholders.

View on SEC.gov

Enliven Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-090821

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.